期刊
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
卷 12, 期 10, 页码 1255-1261出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425255.2016.1223047
关键词
Immunotherapy; lung cancer; melanoma; nivolumab; PD-1; renal cell carcinoma
Introduction: Nivolumab is a programmed cell death 1 (PD-1) inhibitor that has been approved for treatment of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma and classical Hodgkin's lymphoma.Areas covered: This review summarizes the latest evidence on nivolumab's pharmacodynamics, pharmacokinetics, safety and clinical efficacy in different solid tumors, based on published studies and abstracts from international conferences.Expert opinion: Multiple high-level evidence has confirmed the efficacy and safety of nivolumab in solid tumors. Further studies should focus on the identification of potential predictive biomarkers and possibility of combining with other immunotherapeutic or cytotoxic agents. The optimal sequence, treatment duration and possibility of re-challenging patients who had prior nivolumab are yet to be defined.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据